Omnicell (NASDAQ:OMCL) Upgraded by Wall Street Zen to "Strong-Buy" Rating

Omnicell (NASDAQ:OMCL - Get Free Report) was upgraded by Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research note issued on Saturday.

OMCL has been the subject of a number of other research reports. Piper Sandler reissued an "overweight" rating on shares of Omnicell in a report on Friday, May 23rd. JPMorgan Chase & Co. dropped their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, March 20th. Benchmark dropped their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Wells Fargo & Company reissued an "overweight" rating and issued a $37.00 price objective (up previously from $35.00) on shares of Omnicell in a report on Friday, May 23rd. Finally, Bank of America increased their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.83.

Omnicell Price Performance

NASDAQ:OMCL traded down $1.08 during trading hours on Friday, reaching $28.69. 255,198 shares of the company were exchanged, compared to its average volume of 563,698. The company has a current ratio of 1.38, a quick ratio of 1.23 and a debt-to-equity ratio of 0.13. The stock's 50-day moving average is $28.99 and its 200-day moving average is $34.69. The firm has a market cap of $1.34 billion, a PE ratio of 62.37 and a beta of 0.76. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating analysts' consensus estimates of $0.16 by $0.10. The business had revenue of $269.67 million during the quarter, compared to analysts' expectations of $260.18 million. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The company's quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.03 earnings per share. On average, sell-side analysts anticipate that Omnicell will post 1.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in OMCL. Johnson Financial Group Inc. acquired a new position in shares of Omnicell in the fourth quarter valued at approximately $37,000. Headlands Technologies LLC acquired a new position in shares of Omnicell in the fourth quarter valued at approximately $53,000. Huntington National Bank grew its holdings in shares of Omnicell by 236.4% in the fourth quarter. Huntington National Bank now owns 1,359 shares of the company's stock valued at $61,000 after purchasing an additional 955 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in shares of Omnicell in the fourth quarter valued at approximately $101,000. Finally, AlphaQuest LLC grew its holdings in shares of Omnicell by 307.8% in the fourth quarter. AlphaQuest LLC now owns 3,576 shares of the company's stock valued at $159,000 after purchasing an additional 2,699 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.